Cardiometabolic Health Congress

JULY 25, 2024

This fall, we come together for the largest and most innovative cardiometabolic event in honor of the legacy of Dr. George L. Innovations in Cardiorenal Metabolic Medicine The event will focus on the whole spectrum of cardiorenal metabolic disease, including obesity, diabetes, lipids, hypertension, and cardiorenal disease.

Education 100

Education Innovation Risk Factors Obesity 100

American College of Cardiology

NOVEMBER 5, 2024

The idea that obesity increases the risk of heart failure seems like an obvious conclusion. After all, as the Framingham Heart Study clearly showed, obesity and overweight are significantly associated with a higher risk of hypertension, angina and coronary heart disease.

Heart Failure 45

Heart Failure Innovation Angina Obesity 45

ADN Center of Excellence

SEPTEMBER 2, 2024

Factors such as aging populations, rising rates of obesity, hypertension, and other cardiovascular conditions contribute to this increase. From advances in pharmacological treatments to innovative procedures like catheter ablation, the landscape of AFib treatment is continually evolving.

AFIB 59

AFIB Atrial Fibrillation Innovation Heart Rhythm 59

ADN Center of Excellence

SEPTEMBER 2, 2024

Factors such as aging populations, rising rates of obesity, hypertension, and other cardiovascular conditions contribute to this increase. From advances in pharmacological treatments to innovative procedures like catheter ablation, the landscape of AFib treatment is continually evolving.

AFIB 52

AFIB Atrial Fibrillation Innovation Heart Rhythm 52

Cardiometabolic Health Congress

OCTOBER 25, 2024

The Hilton Boston Park Plaza became a hub of innovation, education, and collaboration, uniting nearly 500 clinicians under a shared mission: to redefine cardiometabolic care. The 19th Annual CMHC was more than just CME/CE medical education—it ignited global collaboration and inspired groundbreaking innovations.

CME 64

CME Innovation Education Atherosclerosis 64

Cardiometabolic Health Congress

DECEMBER 5, 2024

As the AHA celebrates its 100th year, the conference reflected on a century of innovation while exploring the future of cardiovascular disease prevention and management. SUMMIT Trial : Weekly subcutaneous tirzepatide showed significant reductions in CV death and HF-related events among patients with HFpEF and obesity.

CME 52

CME Obesity Innovation Cardiovascular Disease 52

DAIC

MAY 21, 2024

The study is the largest and most robust of its kind to date, examining 102,475 Hello Heart users with high BP (hypertension) between January 2018 and December 2022. Founded in 2013, Hello Heart is a digital leader in preventive heart health and a member of the American Heart Association’s Innovators’ Network. of their body weight.

Blood Pressure 52

Blood Pressure Cholesterol Risk Factors BMI 52